Open Access<p>IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells</p>
Author(s) -
Yu Liu,
Gang Chen,
ZeGuang Han,
Han Cheng,
Liang Qiao,
Yumin Li
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s262089
Subject(s) - sorafenib , cd44 , stem cell , cancer research , small hairpin rna , cancer stem cell , hepatocellular carcinoma , flow cytometry , medicine , cell culture , carcinogenesis , cell , cancer , gene knockdown , biology , immunology , microbiology and biotechnology , genetics
Sorafenib is the standard first-line treatment for advanced hepatocellular carcinoma (HCC), even though acquired resistance to sorafenib has been found in many HCC patients, resulting in poor prognosis. Accumulating evidence demonstrates that liver cancer stem cells (LCSCs) contribute to sorafenib resistance in HCC. The inflammatory factor interleukin 6 (IL-6) plays a role in sorafenib resistance in HCC. However, the mechanism by which IL-6 in LCSCs is involved in the process of HCC sorafenib resistance remains elusive.